The object itself
What is Ipamorelin? The shortened chain.
Two amino acids were removed from an older peptide. The shorter chain still released growth hormone, and its hormone selectivity became the interesting part.
The middle was removed; GH release survived
Ipamorelin is a synthetic pentapeptide: a chain of five amino acids. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was derived from GHRP-1 by removing the central Ala-Trp pair; the founding characterization found that the shorter molecule still released GH strongly.
Novo Nordisk developed it in the 1990s under the code NNC 26-0161. Some of its amino acids are unusual, helping the chain resist enzymatic breakdown. The body does not make Ipamorelin; it imitates ghrelin’s action at a receptor rather than being a natural human hormone.
I’m fond of this origin because it is an actual chemical change with a measurable result. It needs no story about a rejuvenating substance the body somehow forgot to make.
Acetate identifies the salt form
“Ipamorelin acetate” identifies a salt form. It does not identify a second therapeutic success or a stronger clinical case. The name alone cannot settle the identity, purity or sterility of research-grade material.
This is where the inspection metaphor becomes literal: a description of the molecule and assurance about a particular preparation are different questions. I won’t accept chemical familiarity as proof of a preparation’s quality.
Is Ipamorelin FDA approved?
No. Ipamorelin has no approved medical indication. On FDA’s page current as of April 22, 2026, Ipamorelin acetate remains in Category 2 under the 503B interim policy, alongside safety warnings. Its 503A nomination was withdrawn, leaving it off that Category 2 list; FDA gives no withdrawal date, and that absence is not approval or a safety clearance.
The advisory committee meeting on October 29, 2024 did not approve it for compounding. I see no permission hiding in the difference between those lists. A withdrawn nomination and an approved medicine are plainly different things.
The oral relatives needed chemical changes
Ipamorelin became a starting point for modified compounds intended to work orally. The work tested derived molecules in animals. It does not establish that ordinary Ipamorelin becomes an effective oral medicine.
The NN703 paper concerns an Ipamorelin-derived compound with its own properties. I care about the changed identity here: engineering a relative is an achievement, but the relative’s results do not belong on Ipamorelin’s label. The clinical record follows that distinction through the studies.